May 16, 2022 5:34pm

A scorecard of earnings releases of covered companies - 31 of 35 - so far

The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status".

5/16 adding Brainstorm Cell Therapeutics (BCLI), Homology Medicine FIXX) and Biostage (BSTG)

 


COMPANY 

SYMBOL NET INCOME

Q1/22 LOSS

Q1/22 LPS

 CASH POSITION RUNWAY

Chinook Therapeutics

 

KDNY

5/12

 

-$31.7 M

-$0.54

$330 M 2025

Agenus

 

AGEN

 

 

-$51M

-$0.19

$263 M 2025

Alnylam

Pharmaceuticals

ALNY

Q1/22

 

-$234.34 M

 

 

 

Q1/22 - $2.00

 

 

 

$2.24 B

 

 

 

NA

 

 

 

Applied Genetic Technologies

AGTC

 

 

 

 

 

 

Athersys

ATHX

 

 

 

 

  2022

Adverum

Biotechnologies

ADVM

5/12

 

-$37.9 M

-$0.38

$271.1 M 2024

AVROBIO

 

AVRO

 

 

-$29.8 M

-$0.68

$161.7 M Q1/2024

AxoGen

AXGN

Q1/22

 

-$8.5 M

-$0.20

$73.7M

2024

Bellicum

Pharmaceuticals

BLCM

5/12

 

-$7.6 M

-$0.25 $41.3 M 2023

Beam

Therapeutics

BEAM  

-$69.2 M

-$1.01

$1.2 B 2025

BioLife

Solutions

BLFS

5/9

 

-$7.1 M

-$0.17

$59.5 M

2025

Biostage

BSTG

 

-$2.2 M

-$0.20

$700 K

Legal liabilitiesof $1.5 M

and yet another (6th) Private Placement Debt

Q4/22

bluebird bio

 

BLUE

5/9

 

-$122.2 M

-$1.66

$312 M

Q1/2023

Brainstorm Cell Therapeutics

 

BCLI  

-$5.36 M

-$015

$18.4 M 2022

Caribou

Biosciences 

CRBU  

 

 

   
Cellectis SA

CLLS

5/12

 

-$32 M

-$0.70

$142 M

2025

CRISPR

Therapeutics

CRSP

5/9

 

-$179.2 M

-$2.32

 $2,221.3 M 1H/2025

Editas

Medicine

EDIT

Q1/22

 

-$50.15 M

 

 

 

-$0.74

 

 

 

$566.4 M

 

 

 

Q1/2024

 

 

 

Fate

Therapeutics

FATE

Q1/22

 

 

-$65.9 M

 

-$0.68

$641.7 M

2024

Global Blood

Therapeutics

GBT

Q1/22

 

-$81.4 M

 

-$1.26 

 

$662.1M

Q1/25

Homology

Medicine

FIXX

+$92.1 M or

+$1.59 per share

 

  $256.1 M 2H/2024

Intellia

Therapeutics

NTLA

 

 

-$146.9 M

-$1.96

 $994.7 M

(-$38.9 M ATM and -$8.4 ESOP drawdown

2024

Precigen

PGEN

5/9

 

 

-$19.3 M

-$0.10

$142.1 M 2024

Ionis

Pharmaceuticals

IONS

Q1/22

 

 

Q1/22 -$65 M

 

 

 

Q1/22 -$0.46

 

 

 

$2.1 B

 

 

 

N/A

 

 

 

Mesoblast

MESO

 

 

 

    2023
MiMedx Group

MDXG

Q1/22

 

 

 

 

 

-$10.5 M

 

 

 

 

 

 

-$0.11

 

 

 

 

 

 

$75.7 M

 

 

 

 

 

2024

 

 

 

 

 

Pluristem

Therapeutics

PSTI          

Regenxbio

 

RGNX

Q1/22

 

-$76.7 M

-$1.79

$764.8 M 2025

Sage

Therapeutics

SAGE

Q1/22

 

-122. M

 

 

 

-$2.07

 

 

 

$1.6 B 

 

 

 

2025

 

 

 

Sangamo

Biosciences

SGMO

Q1/22

 

-$44 M

-$0.30

$400.3 M 2023

Solid

Biosciences

SLDB

3/13

 

 

 

  Q3/2023

Ultragenyx

Pharmaceuticals

RARE  

-$152.3 M

-$2.19 

$813.8 M 2024

uniQure N.V.

 

QURE

Q1/22

 

-$46.7 M

-$1.00

$524.9 M 1H/2025

Verastem

Oncology

VSTM

5/9

 

-$17 M

-$0.09

$106.3 M

(-$25 M drawdown from ATM)

2024

Vericel

 

VCEL

Q1/22

 

-$7.1 M

 

 

 

-$0.015

 

 

 

$130 M

 

 

 

2024

 

 

 

Voyager

Therapeutics

VYGR

Q1/22

 

-$21.3 M

 

 

 

 

-$0.56

 

 

 

 

$160.8 M

 

 

 

 

2024